NightHawk Biosciences Inc (NHWK)

[dia76ca]

I have listened to the Presentation several times. Here is what I heard that seems important.

1. They are targeting turning COLD tumours into HOT tumours.

2. Checkpoint inhibitors working alone turn about 10% of COLD tumours into HOT tumours.

3. Adding HS-110 to checkpoint inhibitors turned about 60% of COLD tumours into HOT. This data was based one a very small sample but this data supplemented by additional patients are the basis for receiving a Type C meeting with the FDA to seek guidance as to the approval path for HS-110.

4.HS-110, HS-120 (HS-110 + OX40), PTX-35 and PTX-15 are "all in manufacture". CPRIT grant of $15 million will cover the cost of trials of several combinations of these drugs with checkpoint inhibitors

5. HS-110 plus Opdivo trials have now begun in 8 trial centers.

6. The COG for CAR-T drugs is anywhere from $35,000 to $50,000 for a course of treatment. The COG for HS-110 is under $1,000 for an entire course of treatment(because it is of-the-shelf). Good news for cancer patients and governments looking for reasonable prices for cancer treatments!